尤瑞克林治疗急性脑梗死后吞咽功能障碍的疗效分析

目的观察注射用尤瑞克林治疗急性脑梗死后吞咽功能障碍(SFD)的临床疗效。方法选择急性脑梗死致SFD患者72例,随机分成两组:对照组34例给予急性脑梗死的基础治疗。治疗组38例在对照组基础上加用注射用尤瑞克林0.15 PNA单位。分别治疗20 d后,采用标准吞咽功能评分量表(SSA评分)评定各组治疗前后的吞咽功能缺损程度,进行疗效判定。结果治疗组及对照组在治疗后20 d SSA评分均较治疗前明显降低,治疗组的SSA评分较对照组明显降低(均P0.05)。治疗组的治疗总有效率86.8%显著高于对照组64.7%(均P0.05)。结论尤瑞克林能明显改善急性脑梗死后SFD,并且可能更加安全有效。

Clinical curative effect of urinary kallidinogenase in swallowing functional disturbance after acute cerebral infarction

Objective To observe the clinical curative effect of urinary kallidinogenase injection therapy in swallowing functional disturbance ( SFD ) after acute cerebral infarction .Methods Seventy-two patients with SFD after acute cerebral infarction included in this trial were randomly divided into two groups :36 cases in control group were treated with basic therapy of acute cerebral infarction , and treatment group were treated with urinary kallidinogenase 0.15 PNA unit with injection and combined with control group therapy for 20 d.SSA score was performed to assess the swallowing function defect degree for all cases with pre and post therapy .Results The SSA score of 20 d after therapy in treatment group and control group were significantlt decreased than those before therapy , and the score in the treatment group was significantly lower than that in control group ( all P<0.05 ) .The total effective rate in the treatment group (86.6%) was significantly higher than that in the control group (64.7%) ( all P<0.05) .Conclusion Urinary kallidinogenase injection therapy may be safe and effective to improve the SFD in patients after acute cerebral infarction .